Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of MK-4280A (favezelimab + pembrolizumab) versus regorafenib or TAS-102 in metastatic colorectal cancer
2021-001309-60Phase 3Suspended
- Sponsor
- Merck & Co.
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in metastatic colon cancer (mCRC) comparing MK-4280A with Standard of care (regorafenib or TAS-102) (2 arms). Primary endpoint: Overall Survival. Started Jul 2021; status: suspended.
02
Drugs
favezelimab + pembrolizumab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2021-001309-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001309-60.